TickerTalks
Browse all tickers →
TickerTalks›$TTRX
TTTTRX

Turn Therapeutics Inc.

$TTRX·$310M·Biotechnology·Healthcare
$9.84-2.7%YTD+127.2%1Y+40.6%
Mentions · last 7 days
2026-08-21: 0 posts2026-08-22: 0 posts80%
Price updated 3d ago·X counts updated 8d ago
TTTTRX
$TTRXTurn Therapeutics Inc.
$9.84-2.67%8 posts0%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Today's AI verdict on what's driving $TTRX, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Too early to tellWinding up for a moveAI verdict · as of 2026-08-20

Trading in a tight range and building pressure — a move looks likely soon, but the direction isn't clear yet.

Wound-care/eczema micro-cap biotech up 127% YTD — pre-revenue with an eczema readout coming later this year.

Turn Therapeutics is an emerging-growth micro-cap biotech developing wound-care and dermatology products — the lead program GX-03 targets eczema with a Phase 2 interim data package driving the recent refinement of the trial design. It's a $310M market cap with essentially no revenue and a small burn rate.

  • The eczema program is the near-term catalyst: GX-03 Phase 2 eczema trial refined after interim data with a 2026 readout expected — this is the binary event the tape is anchored on, and the 127% year-to-date run reflects growing expectations for the readout.
  • The financial burn is manageable for the stage: quarterly free cash flow of negative $1.6M and EPS burn of $0.03-$0.09 per quarter — the company is efficiently deploying cash, and the recent Item 3.02 unregistered equity sale is a small non-dilutive maintenance financing.
  • The tape momentum has been striking: 30% of the 52-week range but the stock is at 97% above the 200-day and 19% above the 50-day — this is a genuine post-uplisting momentum-plus-catalyst-anticipation setup rather than fundamental support.

Trajectory is coiling ahead of the H2 2026 GX-03 eczema readout; a positive readout with a specific efficacy signal reprices the stock materially higher (2-4x is typical for eczema-space binary readouts), a soft readout drops the stock significantly given the pre-revenue setup.

What to watch: H2 2026 GX-03 eczema Phase 2 readout plus Nov 12 Q3 earnings — a positive efficacy readout reprices the stock materially higher (2-4x typical for eczema-space binary readouts); a soft readout drops the stock significantly given the pre-revenue setup.

On the calendar: 2026-11-12 — Q3 2026 earnings

binary catalyst pendingmicro capno sentiment

Read the AI verdict + X sentiment for $TTRX

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Develops topical drugs for skin, nail, and eye conditions using proprietary nanoparticle delivery technology to enhance drug penetration.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $TTRX.

Biotechnology · Healthcare

GLP-1 oral formulation competition — emerging clinical data from pipeline challengers — is the central bifurcation: platform holders (LLY, NVO) defend on efficacy breadth while precision oncology names decouple entirely. FDA catalyst cadence over the next 60 days sets the near-term tone.

What this means for $TTRX

Partial — branded pharmaceutical revenue is exposed to patent cliff dynamics and GLP-1 category cannibalization; Turn Therapeutics Inc.

Top industry ETF

$IBBiShares Biotechnology ETF
+12.1%YTD
+51.2%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-40.6How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-49.6%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
0.0%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-2.5%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
0.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-117%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
0.0%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
1.0Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 13, 2026$-0.20$-0.02-900.0%
Q1 2026May 11, 2026$-0.03$-0.02-50.0%
Q4 2025Mar 31, 2026$0.01$-0.05+118.6%
Q3 2025Nov 13, 2025$-0.07$-0.05-37.3%
Next earningsThu, Nov 12·consensus EPS $-0.09

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$0———$-0.03$-1.6M
Q4 FY25$0———$0.01$-1.2M
Q3 FY25$0———$-0.07$-589K
Q2 FY25$0———$-0.09$-500K

Forward consensus

5-year forecast · up to 1 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$500K$500K – $500K-$0.09-$0.09 – -$0.091
FY27$5.0M$5.0M – $5.0M-$0.32-$0.32 – -$0.321
FY28$12.0M$12.0M – $12.0M-$0.45-$0.45 – -$0.451
FY29$15.0M$15.0M – $15.0M-$1.09-$1.09 – -$1.091
FY30$31.4M$31.4M – $31.4M-$1.55-$1.55 – -$1.551

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.1.0×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.30%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+11.8%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+90.5%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatLow float · 10.8M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today0.6% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β2.025-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KUnregistered equity saleAug 188-K — Item 3.02: Unregistered equity sale
AI summary

Turn Therapeutics Inc. (TTRX) filed an 8-K under Item 3.02 (Unregistered Sales of Equity Securities) on August 13, 2026. Item 3.02 discloses the sale of equity securities — common stock, preferred stock, warrants, or convertible notes — that were issued in a private placement exempt from SEC registration under Regulation D or another exemption. For a development-stage biotech like Turn Therapeutics, such sales are a primary capital-raising mechanism. Investors should review the filing for the type of securities issued, total proceeds raised, the offering price relative to market price, and any conversion or warrant exercise terms that could affect future dilution.

8-KPress release / Reg FDAug 178-K — Item 7.01: Press release / Reg FD
AI summary

Turn Therapeutics Inc. (TTRX) filed an Item 7.01 (Regulation FD) 8-K on August 14, 2026, to broadly disseminate material information shared in a non-public setting. For a clinical-stage biotechnology company like Turn Therapeutics — which is developing epigenetic medicines targeting aging-related diseases — Reg FD filings typically accompany conference presentations, investor day materials, or pipeline update decks. The attached exhibit likely covers clinical program status, upcoming milestone catalysts, and financial runway commentary. Investors should review the exhibit for any new data, clinical read-outs, or partnership updates that could serve as near-term stock catalysts for this early-stage company.

8-KPress release / Reg FDJul 288-K — Item 7.01: Press release / Reg FD
AI summary

Turn Therapeutics Inc. filed an 8-K on July 28, 2026 under Item 7.01 to furnish an updated investor presentation as a Regulation FD disclosure. The company, a Westlake Village, California-based emerging growth biotech listed on the Nasdaq, furnished the presentation as an exhibit. Turn Therapeutics is focused on epigenetic therapies and gene regulation; investor presentations of this type typically update the clinical pipeline status, corporate milestones, and financing runway. The presentation is furnished rather than filed, meaning it is not subject to Section 18 Exchange Act liabilities, and is accessible as an exhibit to this filing.

8-KPress release / Reg FDJul 78-K — Item 7.01: Press release / Reg FD
AI summary

Turn Therapeutics Inc. issued a press release and an updated investor presentation on July 7, 2026 under Regulation FD. Both documents are furnished as exhibits (not filed) and their specific content is not reproduced in the filing body excerpt. Reg FD update — topic and substance are in the attached exhibits; investors should review the press release and investor presentation for any material clinical or pipeline news.

8-KPress release / Reg FDJun 38-K — Item 7.01: Press release / Reg FD
AI summary

TTRX (TTRX) disclosed its addition to Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 under 8-K Item 8.01 (other events). Index inclusions are significant because they trigger automatic buying from passive index funds and ETFs that track the benchmark, often resulting in increased share price and trading volume. Index providers typically announce additions in advance of the effective rebalancing date, giving institutions time to adjust their holdings. The event increases TTRX's institutional ownership base and enhances its market visibility and liquidity profile.

8-KPress release / Reg FDJun 18-K — Item 7.01: Press release / Reg FD
AI summary

Turn Therapeutics (TTRX) issued a press release on June 1, 2026; full content in Exhibit 99.1 with no details in the filing body. Body unavailable — exhibit-only press release.

8-KPress release / Reg FDMay 278-K — Item 7.01: Press release / Reg FD
AI summary

Turn Therapeutics Inc. filed an 8-K under Item 7.01 (Regulation FD) on May 27, 2026, attaching a press release as Exhibit 99.1. The 8-K body contains only boilerplate Reg FD disclosure language; the actual content of the press release — the subject, topic, or any material information — is in Exhibit 99.1 and is not available in the excerpt. Body unavailable — Reg FD exhibit text not included in the body excerpt.

8-KPress release / Reg FDMay 198-K — Item 7.01: Press release / Reg FD
AI summary

Turn Therapeutics Inc. (TTRX) filed an 8-K on May 19, 2026 under Item 7.01 (Regulation FD Disclosure). Turn Therapeutics is a Westlake Village, California-based biopharmaceutical company listed on Nasdaq. Reg FD disclosures for a clinical-stage biotech typically accompany investor presentations at conferences or pipeline data updates.

+ 15 other (3 earnings 8-Ks · 2 10-Qs · 2 8-Ks · 2 EFFECTs) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Turn Therapeutics Announces New Peer-Reviewed Research Showing GX-03 Selectively Reduces Key Drivers of Skin Inflammation and Itchgurufocus.com·11d agoTurn Therapeutics Announces New Peer-Reviewed Research Showing GX-03 Selectively Reduces Key Drivers of Skin Inflammation and Itchbusinesswire.com·11d agoTurn Therapeutics Provides Corporate Updates and Reports Second Quarter 2026 Financial Resultsbusinesswire.com·19d agoTurn Therapeutics to Ring the Nasdaq Closing Bell on Monday, August 10, 2026gurufocus.com·34d agoTurn Therapeutics to Ring the Nasdaq Closing Bell on Monday, August 10, 2026businesswire.com·34d ago

In themes

Explore the broader themes this ticker is being talked about under.

Trending on X

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$MRNA$ALT$AURA$IOVA$NWBO$SLS$AMLX$ABCL
Voices on X · last 7 days

No standout posts about $TTRX on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport